A recent study demonstrated that amlexanox, a dual inhibitor of TBK1 and IKKε, can reduce hepatic inflammatory reaction by inhibiting TBK1/IKKε activities, and consequently reducing obesity and insulin resistance.22 Also, loss of TBK1 kinase activity or IKKε protects mice from high fat diet‐induced metabolic dysfunction.23, 24. The gene discussed is TBK1; the disease is obesity due to melanocortin 4 receptor deficiency.